Lap C, Abrahim M, Nassereddine S
Ann Hematol. 2023; 103(7):2215-2229.
PMID: 37975931
DOI: 10.1007/s00277-023-05545-3.
Ma H, Cui J, Liu Z, Fang W, Lu S, Cao S
Oncogene. 2023; 42(45):3331-3343.
PMID: 37752234
DOI: 10.1038/s41388-023-02848-7.
Lagunas-Rangel F
Hematol Oncol. 2022; 41(1):26-38.
PMID: 36131612
PMC: 10087755.
DOI: 10.1002/hon.3076.
Yao M, Wang Y, Zhao Y, Ling L, He Y, Wen J
Am J Cancer Res. 2022; 12(8):3829-3842.
PMID: 36119822
PMC: 9442011.
Wang J, Li D, Zhao B, Kim J, Sui G, Shi J
Int J Mol Sci. 2022; 23(5).
PMID: 35269825
PMC: 8911024.
DOI: 10.3390/ijms23052672.
Rapid and Sensitive Diagnosis of Drug-Resistant FLT3-F691L Mutation by CRISPR Detection.
Liu Y, Chen Y, Huang S, Ma X, Huang X, Wang X
Front Mol Biosci. 2021; 8:753276.
PMID: 34760927
PMC: 8574994.
DOI: 10.3389/fmolb.2021.753276.
Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.
Zhang L, Lakkaniga N, Bharate J, Mcconnell N, Wang X, Kharbanda A
Eur J Med Chem. 2021; 225:113776.
PMID: 34479037
PMC: 8585723.
DOI: 10.1016/j.ejmech.2021.113776.
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Swaminathan M, Kantarjian H, Levis M, Guerra V, Borthakur G, Alvarado Y
Haematologica. 2021; 106(8):2121-2130.
PMID: 33853292
PMC: 8327731.
DOI: 10.3324/haematol.2020.263392.
Upfront Treatment of FLT3-Mutated AML: A Look Back at the RATIFY Trial and Beyond.
Keiffer G, Aderhold K, Palmisiano N
Front Oncol. 2021; 10:562219.
PMID: 33415071
PMC: 7783448.
DOI: 10.3389/fonc.2020.562219.
Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia.
Damnernsawad A, Bottomly D, Kurtz S, Eide C, McWeeney S, Tyner J
Haematologica. 2020; 107(1):77-85.
PMID: 33375770
PMC: 8719098.
DOI: 10.3324/haematol.2020.257964.
Potential targeting of FLT3 acute myeloid leukemia.
Ambinder A, Levis M
Haematologica. 2020; 106(3):671-681.
PMID: 32703795
PMC: 7927884.
DOI: 10.3324/haematol.2019.240754.
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Hamid A, Petreaca R
Cancers (Basel). 2020; 12(4).
PMID: 32283832
PMC: 7226513.
DOI: 10.3390/cancers12040927.
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.
Tarver T, Hill J, Rahmat L, Perl A, Bahceci E, Mori K
Blood Adv. 2020; 4(3):514-524.
PMID: 32040554
PMC: 7013266.
DOI: 10.1182/bloodadvances.2019000919.
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.
Elgamal O, Mehmood A, Jeon J, Carmichael B, Lehman A, Orwick S
J Hematol Oncol. 2020; 13(1):8.
PMID: 31992353
PMC: 6988309.
DOI: 10.1186/s13045-019-0821-7.
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Weisberg E, Meng C, Case A, Sattler M, Tiv H, Gokhale P
Br J Haematol. 2019; 187(4):488-501.
PMID: 31309543
PMC: 7887860.
DOI: 10.1111/bjh.16092.
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.
Zhang H, Savage S, Schultz A, Bottomly D, White L, Segerdell E
Nat Commun. 2019; 10(1):244.
PMID: 30651561
PMC: 6335421.
DOI: 10.1038/s41467-018-08263-x.
Novel Agents for Acute Myeloid Leukemia.
Luppi M, Fabbiano F, Visani G, Martinelli G, Venditti A
Cancers (Basel). 2018; 10(11).
PMID: 30423907
PMC: 6267447.
DOI: 10.3390/cancers10110429.
Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6.
Li Y, Yu S, Yan P, Gong D, Wu F, He Z
Oncotarget. 2017; 8(61):103087-103099.
PMID: 29262547
PMC: 5732713.
DOI: 10.18632/oncotarget.20710.
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.
Smith C, Paguirigan A, Jeschke G, Lin K, Massi E, Tarver T
Blood. 2017; 130(1):48-58.
PMID: 28490572
PMC: 5501146.
DOI: 10.1182/blood-2016-04-711820.
FLT3-ITD and its current role in acute myeloid leukaemia.
Lagunas-Rangel F, Chavez-Valencia V
Med Oncol. 2017; 34(6):114.
PMID: 28470536
DOI: 10.1007/s12032-017-0970-x.
